Patients with an objective response or stable disease at week 12 received 4 additional doses of rituximab ( at months 3 , 5 , 7 , and 9 ) ; patients who received rituximab/bevacizumab also received bevacizumab 10 mg/kg I.V. every 2 weeks for 16 doses .